On November 2, Moscow hosted the Vademecum MedDay industry forum, the strategic partner of which was the Pharmasyntez Group of Companies. The event brought together the industry leaders and was focused to figuring out how to accomplish the main goal of national healthcare, which was to create a unified medical system that would be resistant to disturbances.

Nikita Punia, Executive Director of the Pharmasyntez Group of Companies, spoke at the session devoted to the affordability of the medications and the import substitution potentials in the modern reality.

“The main goal of the healthcare system is to make medications affordable worldwide. However, not countries every country at can afford building costly molecules manufacturing factories. And global giants, including the Russian ones, which actively promote exports come to their rescue. The Pharmasyntez Group of Companies is one of them. Exporting is one of our top priorities, we rapidly develop it by entering the markets of friendly nations.

At the same time, it is worth remembering about the importance of import substitution for providing our country with modern high-quality medications. Today the Pharmasyntez Group of Companies produces medications in 22 drug segments, while constantly expanding its portfolio and continuing to go forward. The company registers 50 molecules per year and will be able to introduce new international projects to the market in the nearest future. Not long ago, the Pharmasyntez Group of Companies launched the manufacture of hormonal preparations, which became a part of the import substitution process. Thus, the governmental support is essential for us to be able to launch them onto the market.

In 2024, Russia is supposed to undergo an experiment, within the framework of Pharma-2030 strategy, of creating a pharmaceutical substances traceability system, which is of great importance while implementing the “second wheel rule” as the evidence basis. Once created, such traceability system will serve as a kind of protection for the investors who will invest in the creation of the pharmaceutical substances manufacture, as 95 % of the pharmaceutical substances are being imported to Russia from abroad today. The Pharmasyntez Group of Companies factory in Bratsk produces almost 100 tons of pharmaceutical substances per year for the treatment of socially significant diseases. But there should be dozens of similar factories, not just a few of them. Provided that there’ll be the support enhancement of the domestic pharmaceutical substances manufacturers, our company is willing to gain traction and increase production volumes, making its contribution to the national drug sustainability of drug supply,” shared Nikita Punia.